Research Article

Division of Infectious Diseases, Brown University, Providence, RI, USA; The Miriam Hospital, RISE 154, 164 Summit Avenue, Providence, RI 02906, USA

Center for Computational Molecular Biology, Brown University, Providence, RI, USA

Joseph W Hogan

Center for Statistical Sciences, Brown University, Providence, RI, USA

Search for more papers by this author

Sorin Istrail

Center for Computational Molecular Biology, Brown University, Providence, RI, USA

Search for more papers by this author

Allison DeLong

Center for Statistical Sciences, Brown University, Providence, RI, USA

Search for more papers by this author

David A Katzenstein

Division of Infectious Diseases, Stanford University, Stanford, CA, USA

Search for more papers by this author

Rami Kantor

* Author for correspondence

Division of Infectious Diseases, Brown University, Providence, RI, USA; The Miriam Hospital, RISE 154, 164 Summit Avenue, Providence, RI 02906, USA.

Search for more papers by this author

Email the corresponding author at rkantor@brown.edu

Published Online:17 May 2012https://doi.org/10.2217/fvl.12.37

View article

Abstract

Aims: HIV-1 sequence diversity can affect host immune responses and phenotypic characteristics such as antiretroviral drug resistance. Current HIV-1 sequence diversity classification uses phylogeny-based methods to identify subtypes and recombinants, which may overlook distinct subpopulations within subtypes. While local epidemic studies have characterized sequence-level clustering within subtypes using phylogeny, identification of new genotype–phenotype associations are based on mutational correlations at individual sequence positions. We perform a systematic, global analysis of position-specific pol gene sequence variation across geographic regions within HIV-1 subtypes to characterize subpopulation differences that may be missed by standard subtyping methods and sequence-level phylogenetic clustering analyses. Materials & methods: Analysis was performed on a large, globally diverse, cross-sectional pol sequence dataset. Sequences were partitioned into subtypes and geographic subpopulations within subtypes. For each subtype, we identified positions that varied according to geography using VESPA (viral epidemiology signature pattern analysis) to identify sequence signature differences and a likelihood ratio test adjusted for multiple comparisons to characterize differences in amino acid (AA) frequencies, including minority mutations. Synonymous nonsynonymous analysis program (SNAP) was used to explore the role of evolutionary selection witihin subtype C. Results: In 7693 protease (PR) and reverse transcriptase (RT) sequences from untreated patients in multiple geographic regions, 11 PR and 11 RT positions exhibited sequence signature differences within subtypes. Thirty six PR and 80 RT positions exhibited within-subtype geography-dependent differences in AA distributions, including minority mutations, at both conserved and variable loci. Among subtype C samples from India and South Africa, nine PR and nine RT positions had significantly different AA distributions, including one PR and five RT positions that differed in consensus AA between regions. A selection analysis of subtype C using SNAP demonstrated that estimated rates of nonsynonymous and synonymous mutations are consistent with the possibility of positive selection across geographic subpopulations within subtypes. Conclusion: We characterized systematic genotypic pol differences across geographic regions within subtypes that are not captured by the subtyping nomenclature. Awareness of such differences may improve the interpretation of future studies determining the phenotypic consequences of genetic backgrounds.

Keywords:

References

1 Kantor R, Katzenstein DA, Efron B et al. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med.2(4),e112 (2005).
MedlineGoogle Scholar
2 Rhee SY, Gonzales MJ, Kantor R, Betts BJ, Ravela J, Shafer RW. Human immunodeficiency virus reverse transcriptaseand protease sequence database. Nucleic Acids Res.31(1),298–303 (2003).
Medline CASGoogle Scholar
3 Johnson VA, Calvez V, Günthard HF et al. 2011 Update of the drug resistance mutations in HIV-1. HIV Med.18,156–163 (2010).
Google Scholar
4 Chan PA, Kantor R. Transmitted drug resistance in nonsubtype B HIV-1 infection. HIV Therapy3(5),447–465 (2009).
CASGoogle Scholar
5 Frahm N, Goulder PJR, Brander C. Total assessment of HIV-specific CTL responses: epitope clustering, processing preferences, and the impact of HIV sequence heterogeneity. In: HIV Molecular Immunology 2002. Korber BT, Brander C, Haynes BF et al. (Eds). Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, NM, USA 3–22 (2002).
Google Scholar
6 Grossman Z, Paxinos EE, Averbuch D et al. Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir. Antimicrob. Agents Chemother.48(6),2159–2165 (2004).
Medline CASGoogle Scholar
7 Myers RE, Gale CV, Harrison A, Takeuchi Y, Kellam P. A statistical model for HIV-1 sequence classification using the subtype analyser (STAR). Bioinformatics21(17),3535–3540 (2005).
Medline CASGoogle Scholar
8 Brenner BG, Oliveira M, Doualla-Bell F et al. HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS20(9),F9–F13 (2006).
Medline CASGoogle Scholar
9 Calazans A, Brindeiro R, Brindeiro P et al. Low accumulation of L90M in protease from subtype F HIV-1 with resistance to protease inhibitors is caused by the L89M polymorphism. J. Infect. Dis.191,1961–1970 (2005).
Medline CASGoogle Scholar
10 Taylor BS, Sobieszczyk ME, McCutchan FE, Hammer SM. The challenge of HIV-1 subtype diversity. N. Engl. J. Med.358(15),1590–1602 (2008).
Medline CASGoogle Scholar
11 Ou CY, Weniger BG, Luo CC et al. Independent introduction of two major HIV-1 genotypes into distinct high-risk populations in Thailand. Lancet341(8854),1171–1174 (1993).
Medline CASGoogle Scholar
12 Abebe A, Lukashov VV, Rinke de Wit TF et al. Timing of the introduction into Ethiopia of subcluster C´ of HIV type 1 subtype C. AIDS Res. Hum. Retroviruses17(7),657–661 (2001).
Medline CASGoogle Scholar
13 Abebe A, Pollakis G, Fontanet AL et al. Identification of a genetic subcluster of HIV type 1 subtype C (C´) widespread in Ethiopia. AIDS Res. Hum. Retroviruses16(17),1909–1914 (2000).
Medline CASGoogle Scholar
14 Ou C, Takebe Y, Luo C et al. Wide distribution of two subtypes of HIV-1 in Thailand. AIDS Res. Hum. Retroviruses8(8),1471–1472 (1992).
Medline CASGoogle Scholar
15 Kuiken CL, Goudsmit J. Silent mutation pattern in V3 sequences distinguishes virus according to risk group in Europe. AIDS Res. Hum. Retroviruses10(3),319–320 (1994).
Medline CASGoogle Scholar
16 Adwan G, Papa A, Kouidou S et al. HIV type 1 sequences with GGC substitution in injecting drug users in Greece. AIDS Res. Hum. Retroviruses15(7),679–680 (1999).
Medline CASGoogle Scholar
17 Shankarappa R, Chatterjee R, Learn GH et al. Human immunodeficiency virus type 1 env sequences from Calcutta in eastern India: identification of features that distinguish subtype C sequences in India from other subtype C sequences. J. Virol.75(21),10479–10487 (2001).
Medline CASGoogle Scholar
18 Seth P. Evolution of HIV-1 in India. Indian J. Virol.1–5 (2010).
MedlineGoogle Scholar
19 Kalpana A, Srikanth T, Abhay J, Sushama J, Swarali K, Ramesh P. gp120 sequences from HIV type 1 subtype C early seroconverters in India. AIDS Res. Hum. Retroviruses20(8),889–894 (2004).
Medline CASGoogle Scholar
20 Kalish ML, Baldwin A, Raktham S et al. The evolving molecular epidemiology of HIV-1 envelope subtypes in injecting drug users in Bangkok, Thailand: implications for HIV vaccine trials. AIDS9(8),851 (1995).
Medline CASGoogle Scholar
21 Subbarao S, Limpakarnjanarat K, Mastro TD et al. HIV type 1 in Thailand, 1994–1995: persistence of two subtypes with low genetic diversity. AIDS Res. Hum. Retroviruses14(4),319–327 (1998).
Medline CASGoogle Scholar
22 Soares MA, de Oliveira T, Brindeiro RM et al. A specific subtype C of human immunodeficiency virus type 1 circulates in Brazil. AIDS17(1),11 (2003).
Medline CASGoogle Scholar
23 Ojesina AI, Kanki PJ. HIV-1 subtype and reverse transcriptase genotype: role for geographical location and founder effects. PLoS Med.3(12),e540 (2006).
MedlineGoogle Scholar
24 Neogi U, Sahoo PN, Kumar R, De Costa A, Shet A. Characterization of HIV type 1 subtype C protease gene: selection of L63P mutation in protease inhibitor-naive indian patients. AIDS Res. Hum. Retroviruses27(11),1249–1253 (2011).
Medline CASGoogle Scholar
25 Neogi U, Prarthana BS, Gupta S et al. Naturally occurring polymorphisms and primary drug resistance profile among antiretroviral-naive individuals in Bangalore, India. AIDS Res. Hum. Retroviruses26(10),1097–1101 (2010).
Medline CASGoogle Scholar
26 Bello G, Passaes CP., Guimarães ML et al. Origin and evolutionary history of HIV-1 subtype C in Brazil. AIDS22(15),1993 (2008).
MedlineGoogle Scholar
27 De Oliveira T, Pillay D, Gifford RJ. The HIV-1 subtype C epidemic in South America is linked to the United Kingdom. PloS One5(2),e9311 (2010).
MedlineGoogle Scholar
28 Morgado MG, Sabino EC, Shpaer EG et al. V3 region polymorphisms in HIV-1 from Brazil: prevalence of subtype B strains divergent from North American/European prototype and detection of subtype F. AIDS Res. Hum. Retroviruses10(5),569–576 (1994).
Medline CASGoogle Scholar
29 Ana V, Koko O. Close phylogenetic relationship between Angolan and Romanian HIV-1 subtype F1 isolates. Reterovirology6,39 (2009).
MedlineGoogle Scholar
30 Paraskevis D, Pybus O, Magiorkinis G et al. Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach. Retrovirology6(1),49 (2009).
MedlineGoogle Scholar
31 Mehta SR, Wertheim JO, Delport W et al. Using phylogeography to characterize the origins of the HIV-1 subtype F epidemic in Romania. Infect. Genet. Evol.11(5),975–979 (2011).
MedlineGoogle Scholar
32 Véras NM, Gray RR, de Macedo Brígido LF, Rodrigues R, Salemi M. High-resolution phylogenetics and phylogeography of human immunodeficiency virus type 1 subtype C epidemic in South America. J. Gen. Virol.92(7),1698–1709 (2011).
Medline CASGoogle Scholar
33 Véras NM, Santoro MM, Gray RR et al. Molecular epidemiology of HIV type 1 CRF02_AG in Cameroon and African patients living in Italy. AIDS Res. Hum. Retroviruses27(11),1173–1182 (2011).
MedlineGoogle Scholar
34 Gao F, Vidal N, Li Y et al. Evidence of two distinct subsubtypes within the HIV-1 subtype A radiation. AIDS Res. Hum. Retroviruses17(8),675–688 (2001).
MedlineGoogle Scholar
35 Meloni ST, Kim B, Sankale JL et al. Distinct human immunodeficiency virus type 1 subtype A virus circulating in west Africa: sub-subtype A3. J. Virol.78(22),12438–12445 (2004).
Medline CASGoogle Scholar
36 Vidal N, Mulanga C, Bazepeo SE, Lepira F, Delaporte E, Peeters M. Identification and molecular characterization of subsubtype A4 in central Africa. AIDS Res. Hum. Retroviruses22(2),182–187 (2006).
Medline CASGoogle Scholar
37 Triques K, Bourgeois A, Saragosti S et al. High diversity of HIV-1 subtype F strains in central Africa. Virology259(1),99–109 (1999).
Medline CASGoogle Scholar
38 Triques K, Bourgeois A, Vidal N et al. Near-full-length genome sequencing of divergent African HIV type 1 subtype F viruses leads to the identification of a new HIV type 1 subtype designated K. AIDS Res. Hum. Retroviruses16(2),139–151 (2000).
Medline CASGoogle Scholar
39 Kanki PJ, Hamel DJ, Sankalé JL et al. Human immunodeficiency virus type 1 subtypes differ in disease progression. J. Infect. Dis.179,68–73 (1999).
Medline CASGoogle Scholar
40 Boivin MJ, Ruel TD, Boal HE et al. HIV-subtype A is associated with poorer neuropsychological performance compared with subtype D in antiretroviral therapy-naive Ugandan children. AIDS24(8),1163–1170 (2010).
Medline CASGoogle Scholar
41 Benson DA, Boguski MS, Lipman DJ et al. GenBank. Nucleic Acids Res.27(1),12 (1999).
Medline CASGoogle Scholar
42 Land S, Cunningham P, Zhou J et al. TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories. J. Virol. Methods159(2),185–193 (2009)
Medline CASGoogle Scholar
43 de Oliveira T, Shafer RW, Seebregts C. Public database for HIV drug resistance in southern Africa. Nature464(7289),673 (2010).
Medline CASGoogle Scholar
44 Novitsky V, Wester CW, DeGruttola V et al. The reverse transcriptase 67N 70R 215Y genotype is the predominant TAM pathway associated with virologic failure among HIV type 1C-infected adults treated with ZDV/ddI-containing HAART in southern Africa. AIDS Res. Hum. Retroviruses23(7),868–878 (2007).
Medline CASGoogle Scholar
45 Kuiken C, Leitner T. HIV-1 subtyping. In: Computational and Evolutionary Analysis of HIV Molecular Sequences. Rodrigo AG, Learn GH Jr (Eds). Kluwer Academic Publishers, MA, USA, 27–53 (2002).
Google Scholar
46 Edgar RC. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res.32(5),1792–1797 (2004).
Medline CASGoogle Scholar
47 Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS20(16),W13–W23 (2006).
MedlineGoogle Scholar
48 Korber B, Myers G. Signature pattern analysis: a method for assessing viral sequence relatedness. AIDS Res. Hum. Retroviruses8(9),1549–1560 (1992).
Medline CASGoogle Scholar
49 Agresti A. Categorical Data Analysis (2nd Edition). Wiley-Interscience, NJ, USA (2002).
Google Scholar
50 Quinn GP, Keough MJ. Experimental Design and Data Analysis for Biologists. Cambridge University Press, UK (2002).
Google Scholar
51 Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Series B Stat. Methodol.289–300 (1995).
Google Scholar
52 Shannon CE, Weaver W. A mathematical theory of communication. Bell Syst. Tech. J.27,379–423 (1948).
Google Scholar
53 Korber B. HIV signature and sequence variation analysis. In: Computational Analysis of HIV Molecular Sequences. Kluwer Academic Publishers, MA, USA 4,55–72 (2000).
Google Scholar
54 Rodrigues R, Scherer LC, Oliveira CM et al. Low prevalence of primary antiretroviral resistance mutations and predominance of HIV-1 clade C at polymerase gene in newly diagnosed individuals from south Brazil. Virus Res.116(1–2),201–207 (2006).
Medline CASGoogle Scholar
55 Brígido LFM, Ferreira JLP, Almeida VC et al. Southern Brazil HIV type 1 C expansion into the State of São Paulo, Brazil. AIDS Res. Hum. Retroviruses27(3),339–344 (2011).
Medline CASGoogle Scholar
56 Castro-Nallar E, Pérez-Losada M, Burton GF, Crandall KA. The evolution of HIV: inferences using phylogenetics. Mol. Phylogenet. Evol.62(2),777–792 (2011).
MedlineGoogle Scholar
57 Tomiyama H, Sakaguchi T, Miwa K et al. Identification of multiple HIV-1 CTL epitopes presented by HLA-B*5101 molecules. Hum. Immunol.60(3),177–186 (1999).
Medline CASGoogle Scholar
58 Kawashima Y, Pfafferott K, Frater J et al. Adaptation of HIV-1 to human leukocyte antigen class I. Nature458(7238),641–645 (2009).
Medline CASGoogle Scholar
59 Kaslow RA, Carrington M, Apple R et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV–1 infection. Nature Med.2(4),405–411 (1996).
Medline CASGoogle Scholar
60 Scorza Smeraldi R, Fabio G, Lazzarin A et al. HLA-associated susceptibility to AIDS: HLA B35 is a major risk factor for Italian HIV-infected intravenous drug addicts. Hum. Immunol.22(2),73–79 (1988).
Medline CASGoogle Scholar
61 Scorza Smeraldi R, Lazzarin A, Moroni M, Fabio G, Eisera NB, Zanussi C. HLA-associated susceptibility to acquired immunodeficiency syndrome in Italian patients with human-immunodeficiency-virus infection. Lancet328(8517),1187–1189 (1986).
Google Scholar
62 Just JJ. Genetic predisposition to HIV-1 infection and acquired immune deficiency virus syndrome: a review of the literature examining associations with HLA. Hum. Immunol.44(3),156–169 (1995).
Medline CASGoogle Scholar
63 Yusim K, Kesmir C, Gaschen B et al. Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation. J. Virol.76(17),8757–8768 (2002).
Medline CASGoogle Scholar
64 Shafer RW, Rhee SY, Bennett DE. Consensus drug resistance mutations for epidemiological surveillance: basic principles and potential controversies. Antivir. Ther.13,59–68 (2008).
MedlineGoogle Scholar
101 Los Alamos HIV databases. www.hiv.lanl.gov
Google Scholar

Vol. 7, No. 5

Metrics

Downloaded 74 times

History

Published online 17 May 2012

Published in print May 2012

Information

Keywords

Financial & competing interests disclosure

A DeLong, JW Hogan, A Huang, D Katzenstein and R Kantor are funded by R01AI66922; A Huang, A DeLong, JW Hogan and R Kantor are funded by CFAR-P30AI042853; and A Huang was funded by T32 grant T32DA13911-10, all from the NIH. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations.

PDF download

Global analysis of sequence diversity within HIV-1 subtypes across geographic regions

Abstract

References